The fact that migraine therapy is changing is also reflected in the recent publication of the updated S1 guideline “Treatment of migraine attacks and prophylaxis of migraine”. Although triptans are still the standard medication for treating acute migraine attacks, new active ingredients are expanding the treatment arsenal. Progress has also been made in migraine prophylaxis – for example, two new oral CGRP receptor antagonists have established themselves as treatment alternatives. These are just some of the innovations that should contribute to optimized care for migraine patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Ischemic stroke: Are smaller or larger brain arteries affected?
Recent study findings on intravenous lysis therapy with fibrinolytic agents
- Interview
“On par with the gold standards for trauma”
- Psychology: Emotional Freedom Techniques (EFT)
Emotional Healing Through Tapping
- Systemic Lupus (SLE): What Does the Diagnosis and Treatment Toolbox Have to Offer?
Treat-to-Target – Consensus Recommendations for GC Tapering and the Use of DMARDs
- Psychedelic-assisted therapy
Current status of PAT
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Psoriasis and Obesity: Effects of Incretin-Based Therapies
Clinical trials shed light on the potential of semaglutide, liraglutide, and tirzepatide
- Non-small-cell lung cancer (NSCLC)